Coldstream Capital Management Inc Protagonist Therapeutics, Inc Transaction History
Coldstream Capital Management Inc
- $4.64 Billion
- Q1 2025
A detailed history of Coldstream Capital Management Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Coldstream Capital Management Inc holds 99 shares of PTGX stock, worth $4,383. This represents 0.0% of its overall portfolio holdings.
Number of Shares
99Holding current value
$4,383% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
275Shares Held
57.1MCall Options Held
605KPut Options Held
297K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$270 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$255 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$253 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$189 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$133 Million5.07% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.17B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...